Congestive Heart Disease Marker Tests Market
Congestive heart disease marker tests are diagnostic tests to measure the concentration of the protein to identify the occurrence and disease phase. The cardiac diseases can be prevented by identifying the heart conditions by cardiac biomarker testing is helpful for the immediate diagnosis and treatment. Cardiac biomarkers evaluate the cardiac function and help in identifying the severity and complexity of procedures to treat CVD. The primary indications for the CVD are acute coronary syndrome (ACS) that include congestive heart failure (CHF), angina pectoris (AP) peripheral artery disease (PAD), acute myocardial infarction (AMI) and others. The causes for CVD are include smoking, high blood pressure, diabetes, inadequate exercise, stress, unhealthy diet, obesity, high blood cholesterol, and alcoholism. The most commonly used cardiac biomarkers for diagnosis of CVD include troponin I and T, CK-MB, BNPs, myoglobin, and IMA, among others.
Increase in geriatric population, rise in funding from private-public organizations for cardiac biomarkers research, and ongoing research and clinical trials for identification of the newer cardiac biomarkers are the key factors boost the congestive heart disease marker tests market over the forecast period. Moreover, promising features such as high accuracy, quick outcomes and economic pricing of cardiac point of care (POC) testing, and increase in the adoption of new diagnostic tools by healthcare professionals and cost affordability for patients might propel the global congestive heart disease marker tests market over the forecast period. However, factors technical problems such as sample collection and storage, stringent regulatory guidelines, lack of reimbursement systems hamper the growth of congestive heart disease marker tests market over the forecast period.
The congestive heart disease marker tests market is segmented on the basis of product type, test type, application, and end-user
Based on product type, the congestive heart disease marker tests market has been segmented into the following:
Based on test type, the congestive heart disease marker tests market has been segmented into the following:
- Myocardial muscle Creatine Kinase (CK-MB)
- Troponins (T and I)
- Ischemia Modified Albumin (IMA)
- NT-proBNP or Brain Natriuretic Peptide (BNP) or
Based on application, the congestive heart disease marker tests market has been segmented into the following:
- Myocardial Infarction
- Acute Coronary Syndrome
- Congestive Heart Failure
Based on the end-user, the congestive heart disease marker tests market has been segmented into the following:
- Diagnostic Centres
Launch of new products, technological advancements, acquisitions and mergers, and collaborations are some key strategies followed by various industry players to increase their share in the congestive heart disease marker test market. For instance, in July 2011, Thermo Fisher Scientific it inked a license agreement with Alere Inc. to develop its novel Thermo Scientific B.R.A.H.M.S. biomarker assays on Alere’s leading point-of-care Triage platform.
Geographically, the congestive heart disease marker tests market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the dominant share owing to increase in the prevalence of congestive heart failures (According to the American Heart Association (AHA), nearly five Mn individuals experience heart failure and about 550,000 new cases are diagnosed each year in the United States). Rising aging population, increase in inclination toward point-of-care testing, and elevated frequency of cardiovascular disorders are the key factors expected to drive the congestive heart disease marker tests market over the forecast period. Europe holds a major share in global congestive heart disease marker tests market attributed to increase in the prevalence of congestive heart failure (According to British Heart Foundation (BHF) approximately 7 Mn people are suffering from the various cardiovascular disease in U.K.). Rise in incidence of congestive heart disease in U.K. (approximately 4000 cases per year in new born babies), increase in the research and development, and novel innovations in congestive heart disease biomarker tests might fuel the growth of the market. The Asia-Pacific is expected to exhibit significant growth over forecast period owing to increase in prevalence of Myocardial Infarction, public–private initiatives to increase the awareness related to early cardiac disease diagnosis in physicians and patients.
Some of the players in congestive heart disease marker test market are F. Hoffmann-La Roche (Switzerland), Siemens AG (Germany), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Nanogen, Inc. (U.S.), bioMérieux SA (France), Alere, Inc. (U.S.), LSI Medience Corporation (Mitsubishi Chemical Holdings Corporation, Japan), Randox Laboratories Ltd (U.K.), Ortho Clinical Diagnostics (The Carlyle Group) (U.S.),and Guangzhou Wondfo Biotech Co. Ltd. (China) to name a few.
- In September 2016, National Institute for Health and Care Excellence developed a Medtech Innovation Briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario